Related Experiment Videos
[Indications for antiplatelet medications].
A Castaigne1, S Benacerraf, A Le Roux
1Fédération des services de médecine cardiologique, Hôpital Henri-Mondor, Créteil.
La Revue Du Praticien
|December 3, 1999
Summary
Platelet-active drugs, including aspirin and newer agents, are effective antithrombotics. Optimal dosing and specific patient populations determine their clinical benefit in preventing cardiovascular events.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Neurology
Context:
- Platelet-active drugs are crucial antithrombotics.
- Current clinical practice does not routinely assess their biological effects.
- Randomized controlled trials (RCTs) have established their clinical efficacy.
Purpose:
- To review the established clinical efficacy of various platelet-active drugs.
- To highlight optimal dosing strategies and specific indications for antithrombotic therapy.
- To compare the effectiveness of aspirin, ticlopidine, clopidogrel, dipyridamole combinations, and glycoprotein IIb/IIIa antagonists.
Summary:
- Aspirin is effective in coronary artery disease and secondary stroke prevention, reducing myocardial infarction, stroke, and cardiac death. Doses between 75-300 mg are recommended, emphasizing the lowest effective dose.
- Ticlopidine and clopidogrel show superiority over aspirin in reducing myocardial infarction in patients with lower limb atherosclerosis and post-stroke.
- Dipyridamole and aspirin combination therapy is superior to aspirin alone for secondary stroke prevention. Glycoprotein IIb/IIIa antagonists reduce myocardial infarction in acute coronary syndromes and angioplasty but do not impact 6-month mortality.
Impact:
- Provides evidence-based guidance on selecting and dosing antithrombotic agents.
- Informs clinical practice for secondary prevention of cardiovascular and cerebrovascular events.
- Identifies specific patient subgroups that benefit most from different antiplatelet therapies.